Latest Breaking News On - Davidp southwell - Page 3 : comparemela.com

TScan Therapeutics, Inc (TCRX) Announces FDA Clearance of Three Investigational NDAs for Treatment of Solid Tumors

TScan Therapeutics, Inc (TCRX) Announces FDA Clearance of Three Investigational NDAs for Treatment of Solid Tumors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Davidp southwellGavin macbeathTscan therapeutics incSecurities exchangeDrug administrationCompany immunobankHeather savelletscan therapeutics incWall streetChief scientificChief executive officerPrivate securities litigation reform actSecurities exchange actFinancial conditionAnnual reportInvestor relationsAllairelifesci advisors

TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDavidp southwellDebora bartonHeather savelleJoyce allaireHematologic malignancies programCompany phaseNovartis institutes for biomedical researchLifesci advisorsSociety for immunotherapy of cancerDrug administrationErnestn morial convention centerAmerican society of hematologyTscan therapeutics incInds for the companyGlobe newswire tscan therapeutics inc

TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures

TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Davidp southwellParag shahHeather savelleJoyce allaireInds for the companyTscan therapeutics incLifesci advisorsExchange commission onGlobe newswire tscan therapeutics incSecurities exchangeWall streetChief executivePrime rateExchange commissionFounding managing directorPrivate securities litigation reform act

TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

10.08.2022 - Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) IND filings .

Sao pauloUnited statesDavidp southwellKai wucherpfennigDebora bartonHeather savelleJoyce allairePontificia universidade catolicaBroad instituteCelgene corporationTscan therapeutics incGlobe newswire tscan therapeutics incAmerican society of geneIovance biotherapeutics incCarisma therapeutics incDana farber cancer institute

TScan Therapeutics, Inc (NASDAQ:TCRX) Short Interest Down 41 9% in May

TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Rating) saw a significant decline in short interest in May. As of May 31st, there was short interest totalling 134,500 shares, a decline of 41.9% from the May 15th total of 231,600 shares. Approximately 1.5% of the shares of the stock are short sold. Based on an average daily […]

Davidp southwellSecurities exchange commissionGoldman sachs group incRenaissance technologiesTscan therapeutics incTscan therapeutics company profile get ratingMarquette asset managementCitadel advisorsGet ratingExchange commissionAsset managementSachs groupTherapeutics company profileTscan therapeuticsNasdaq tcrx